A Systematic Review of the Treatment Outcomes among Prostate Cancer Patients in Africa

References

• Adeloye D, David RA, Aderemi AV, Iseolorunkanmi A, Oyedokun A, Iweala EEJ, et al. An estimate of the incidence of prostate cancer in Africa: a systematic review and meta-analysis. PLoS One. 2016;11(4):e0153496. doi:10.1371/journal.pone.0153496.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Cancer Today [Internet]. 2021. [cited 2021 Nov 15]. Available from: https://gco.iarc.fr/today/home.
   Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–89. doi:10.1002/ijc.33588.
   Web of Science ®Google Scholar
• Rebbeck TR, Devesa SS, Chang B-L, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer. 2013;2013:560857–12. doi:10.1155/2013/560857.
   PubMedGoogle Scholar
• Romero FR, Romero AW, de Almeida RMS, Filho RT. The prevalence of prostate cancer in Brazil is higher in Black men than in White men: systematic review and meta-analysis. Int Braz J Urol. 2012;38(4):440–447. doi:10.1590/s1677-55382012000400002.
   PubMedGoogle Scholar
• Patierno SR. Prostate cancer in focus: current developments in the management of prostate cancer. Clin Adv Hematol Oncol. 2020;18(3):154–156.
   PubMedGoogle Scholar
• Leinwand GZ, Gabrielson AT, Krane LS, Silberstein JL. Rethinking active surveillance for prostate cancer in African American men. Transl Androl Urol. 2018;7(Suppl 4):S397–S410. doi:10.21037/tau.2018.06.19.
   PubMedGoogle Scholar
• Yamoah K, Deville C, Vapiwala N, Spangler E, Zeigler-Johnson CM, Malkowicz B, et al. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol. 2015;33(2):70.e15–70–e22. doi:10.1016/j.urolonc.2014.07.005.
   Google Scholar
• Tsivian M, Bañez LL, Keto CJ, Abern MR, Qi P, Gerber L, et al. African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis. 2013;16(1):91–93. doi:10.1038/pcan.2012.39.
   PubMedGoogle Scholar
• Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807–1823. doi:10.1177/1557988318798279.
   PubMed Web of Science ®Google Scholar
• Mcginley KF, Tay KJ, Moul JW. Prostate cancer in men of African origin. Nat Rev Urol. 2016;13(2):99–107. doi:10.1038/nrurol.2015.298.
   PubMedGoogle Scholar
• Ozyigit G, Onal C, Igdem S, Alicikus ZA, Iribas A, Akin M, et al. Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study. Strahlenther Onkol. 2019;195(10):882–893. doi:10.1007/s00066-019-01476-z.
   PubMedGoogle Scholar
• Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res. 2020;26(17):4551–4558. doi:10.1158/1078-0432.CCR-20-0587.
   PubMedGoogle Scholar
• Santok GDR, Raheem AA, Kim LHC, Chang K, Lum TGH, Chung BH, et al. Prostate-specific antigen 10–20 ng/mL: a predictor of degree of upgrading to ≥8 among patients with biopsy gleason score 6. Investig Clin Urol. 2017;58(2):90–97. doi:10.4111/icu.2017.58.2.90.
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.21349.
   PubMed Web of Science ®Google Scholar
• Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R. Brachytherapy in the management of prostate cancer. Surg Oncol Clin N Am. 2017;26(3):491–513. doi:10.1016/j.soc.2017.01.008.
   PubMedGoogle Scholar
• Vanneste BGL, Van Limbergen EJ, Van Lin EN, Van Roermund JGH, Lambin P. Prostate cancer radiation therapy: what do clinicians have to know? Biomed Res Int. 2016;2016:6829875. doi:10.1155/2016/6829875.
   PubMedGoogle Scholar
• Lambin P, Zindler J, Vanneste BGL, De Voorde L, Van Eekers D, Compter I, et al. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev. 2017;109:131–153. doi:10.1016/j.addr.2016.01.006.
   PubMed Web of Science ®Google Scholar
• Schmid S, Omlin A, Blum D, Strasser F, Gillessen S, Rothermundt C. Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review. Ann Oncol. 2015;26(11):2221–2247. doi:10.1093/annonc/mdv326.
   PubMedGoogle Scholar
• Tran K, Zomer S, Chadder J, Earle C, Fung S, Liu J, et al. Measuring patient-reported outcomes to improve cancer care in Canada: an analysis of provincial survey data. Curr Oncol. 2018;25(2):176–179. doi:10.3747/co.25.3995.
   PubMedGoogle Scholar
• Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Venkat PS, Fink AK, et al. Contemporary radiation treatment of prostate cancer in Africa: a Ghanaian experience. J Glob Oncol. 2018;4:1–13. doi:10.1200/JGO.17.00234.
   PubMedGoogle Scholar
• Lin FP, Groza T, Kocbek S, Antezana E, Epstein RJ. Cancer care treatment outcome ontology: a novel computable ontology for profiling treatment outcomes in patients with solid tumors. JCO Clin Cancer Inform. 2018;2(2):1–14. doi:10.1200/CCI.18.00026.
   Google Scholar
• Stewart LA, PRISMA-IPD Development Group, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657–1665. doi:10.1001/jama.2015.3656.
   PubMed Web of Science ®Google Scholar
• Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation. Int J Evid Based Healthc. 2015;13(3):179–187. doi:10.1097/XEB.0000000000000062.
   PubMed Web of Science ®Google Scholar
• Daoud MA, Aboelnaga EM, Alashry MS, Fathy S, Aletreby MA. Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients. OTT. 2017;10:4981–4988. doi:10.2147/OTT.S141224.
   Google Scholar
• Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Dadzie MA, Fink A, et al. Definitive radiation treatment patterns and outcomes for low and intermediate risk prostate cancer patients: a cross-continental comparative study. Am J Clin Oncol. 2019;42(12):937–944. doi:10.1097/COC.0000000000000589.
   PubMedGoogle Scholar
• Seraphin TP, Joko-Fru WY, Manraj SS, Chokunonga E, Somdyala NIM, Korir A, et al. Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study. Cancer Causes Control. 2021;32(9):1001–1019. doi:10.1007/s10552-021-01453-x.
   PubMed Web of Science ®Google Scholar
• Taha SM, Weng HY, El Imam Mohammed M, Osman YM, N’Dri N, Mohammed SI, et al. Prostate cancer clinical characteristics and outcomes in Central Sudan. Ecancermedicalscience. 2020;14(1116):1116.
   PubMedGoogle Scholar
• Heyns CF, Basson J, Van Der Merwe A, Zarrabi AD. Clinical (non-histological) diagnosis of advanced prostate cancer: evaluation of treatment outcome after androgen deprivation therapy. S Afr J Surg. 2014;52(3):82–85. doi:10.7196/sajs.1689.
   PubMedGoogle Scholar
• Magoha GAO. Management and survival in advanced prostate cancer in Nairobi. East Afr Med J. 2000;77(5):260–263.
   PubMedGoogle Scholar
• Bello JO. Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer. BMC Urol. 2017;17(1):39. doi:10.1186/s12894-017-0228-0.
   PubMed Web of Science ®Google Scholar
• Diallo Y, Kouka SC, Jalloh M, Malad H, NâDiaye MD, Daher M, et al. Metastatic prostate cancer: clinical aspects and therapeutic management in the region of Thies Senegal. Med Surg Urol. 2019;8(4):1–6.
   Google Scholar
• Ondo CZ, Ndiath A, Sarr A, Thiam A, Sine B, Sow O, et al. Metastatic prostate cancer: clinical aspects and treatment limitations in a university hospital center in Senegal. African J Urol. 2021;27(1):1–5.
   Google Scholar
• Nyongole OV, Kivuyo NE, Mushi FA, Akoko LO, Mizinduko M, Mtaturu GF, et al. A retrospective study of patients with castrate resistant prostate cancer at Muhimbili National Hospital, Tanzania. Tanz Med J. 2020;31(2):1–10. doi:10.4314/tmj.v31i2.380.
   Google Scholar
• Akpayak IC, Shuaibu SI, Ofoha CG, Dakum NK, Ramyil VM, Onowa VE, et al. Lower urinary tract symptoms in patients with advanced prostate cancer: what are the outcomes of androgen deprivation therapy? Niger Postgrad Med J. 2020;27(1):49–53. doi:10.4103/npmj.npmj_146_19.
   PubMedGoogle Scholar
• Alhanafy AM, Zanaty F, Ibrahem R, Omar S. Prognostic factors for hormone sensitive metastatic prostate cancer: impact of disease volume. Asian Pacific J Cancer Prev. 2018;19(4):1113–1118.
   PubMedGoogle Scholar
• Badmus TA, Adesunkanmi ARK, Yusuf BM, Oseni GO, Eziyi AK, Bakare TIB, et al. Burden of prostate cancer in southwestern Nigeria. Urology. 2010;76(2):412–416. doi:10.1016/j.urology.2010.03.020.
   PubMedGoogle Scholar
• Beksisa J, Getinet T, Tanie S, Diribi J, Hassen Y. Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study. PLoS One. 2020;15(3):e0229854. doi:10.1371/journal.pone.0229854.
   PubMed Web of Science ®Google Scholar
• Seraphin TP, Joko-Fru WY, Hämmerl L, Griesel M, Mezger NCS, Feuchtner JC, et al. Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: a population-based registry study. Cancer. 2021;127(22):4221–4232. doi:10.1002/cncr.33818.
   PubMedGoogle Scholar
• Ajape A, Ibrahim KOO, Fakeye JA, Abiola OO. An overview of cancer of the prostate diagnosis and management in Nigeria: the experience in a Nigerian tertiary hospital. Ann Afr Med. 2010;9(3):113–117. doi:10.4103/1596-3519.68353.
   PubMedGoogle Scholar
• Dawam D, Rafindadi AH, Kalayi GD. Benign prostatic hyperplasia and prostate carcinoma in native Africans. BJU Int. 2000;85(9):1074–1077. doi:10.1046/j.1464-410x.2000.00677.x.
   PubMedGoogle Scholar
• Ndour NS, Sow Y, Sine B, Ndiaye M, Sarr A, Thiam A, et al. Outcomes of radical prostatectomy in patients with prostate cancer at the Aristide Le Dantec University Hospital. Pan Afr Med J. 2021;38:1–8.
   PubMedGoogle Scholar
• Yahaya JJ, Okecha T, Odida M, Wabinga H. Prognostic factors for overall survival of patients with prostate cancer in Kyadondo County, Uganda. Prostate Cancer. 2020;2020:1–9. doi:10.1155/2020/8517130.
   Google Scholar
• Cassell A, Yunusa B, Jalloh M, Ndoye M, Mbodji MM, Diallo A, et al. Management of advanced and metastatic prostate cancer: a need for a sub-Saharan guideline. J Oncol. 2019;2019:1785428. doi:10.1155/2019/1785428.
   PubMed Web of Science ®Google Scholar
• Stefan DC. Cancer care in Africa: an overview of resources. J Glob Oncol. 2015;1(1):30–36. doi:10.1200/JGO.2015.000406.
   PubMedGoogle Scholar
• Hassanipour S, Delam H, Arab-Zozani M, Abdzadeh EA, Hosseini S, Nikbakht HA, et al. Survival rate of prostate cancer in Asian countries: a systematic review and meta-analysis. Ann Glob Health. 2020;86(1):2. doi:10.5334/aogh.2607.
   PubMed Web of Science ®Google Scholar
• Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019;19(1):19. doi:10.1186/s12894-019-0448-6.
   PubMedGoogle Scholar
• Kirby M, Hirst C, Crawford ED. ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192. doi:10.1111/j.1742-1241.2011.02799.x.
   PubMed Web of Science ®Google Scholar
• Baratedi WM, Tshiamo WB, Mogobe KD, McFarland DM. Barriers to prostate cancer screening by men in sub-Saharan Africa: an integrated review. J Nurs Scholarsh. 2020;52(1):85–94. doi:10.1111/jnu.12529.
   PubMed Web of Science ®Google Scholar
• Marima R, Hull R, Mbeje M, Molefi T, Mathabe K, Elbagory AM, et al. Role of precision oncology in Type II endometrial and prostate cancers in the African population: global cancer genomics disparities. IJMS. 2022;23(2):628. doi:10.3390/ijms23020628.
   Google Scholar
• Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68(3):927–936. doi:10.1158/0008-5472.CAN-07-2608.
   PubMed Web of Science ®Google Scholar
• Lei JH, Liu LR, Wei Q, Yan SB, Song TR, Lin FS, et al. Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer. Sci Rep. 2015;5(1):7713. doi:10.1038/srep07713.
   PubMedGoogle Scholar
• Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177u-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med. 2020;45(12):935–942. doi:10.1097/RLU.0000000000003307.
   PubMedGoogle Scholar
• Ng K, Wilson P, Mutsvangwa K, Hounsome L, Shamash J. Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis. 2021;24(3):718–724. doi:10.1038/s41391-020-00316-x.
   PubMedGoogle Scholar
• Mensah JE, Yarney J, Vanderpuye V, Akpakli E, Tagoe S, Sasu E. Prostate brachytherapy in Ghana: our initial experience. J Contemp Brachytherapy. 2016;8(5):379–385. doi:10.5114/jcb.2016.62972.
   PubMedGoogle Scholar
• El Halim M, Abu Hamar A, Mansour S, El-Shebiney M, El-Bary NMA, Sadaka E, Maria A. Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer. Hematol Oncol Stem Cell Ther. 2010;3(3):121–127. doi:10.1016/S1658-3876(10)50022-0.
   PubMedGoogle Scholar
• Heyns CF, for the South African Triptorelin Study Group, Simonin MP, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92(3):226–231. doi:10.1046/j.1464-410X.2003.04308.x.
   PubMed Web of Science ®Google Scholar